Bluepharma Industria Farmaceutica S.A. — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

0 Recruiting

17 Completed trials

1 Countries active

6 Unique IMPs

100% Results reported

Other

Other: 17

Oversight events:

2 temporary halts across 2 trials

View oversight register →

100%

17 of 17 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Thrombocytopenia 2

Top IMPs

ELTROMBOPAG OLAMINE 2 LENVATINIB 1 LENVATINIB MESILATE 1 NILOTINIB 1 NILOTINIB HYDROCHLORIDE 1 NILOTINIB HYDROCHLORIDE MONOHYDRATE 1

All trials

17 total

Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions Ended

2025-522259-24-00 1 country
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions Ended

2025-520716-34-00 1 country
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions. Ended

2024-515947-49-00 1 country
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended

2024-511647-25-00 1 country
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512908-19-00 1 country
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-514448-10-00 1 country
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512910-16-00 1 country
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditio… Ended

2024-512853-26-00 1 country
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions Ended

2024-512857-25-00 1 country
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2023-508339-29-00 1 country
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended

2023-504516-15-00 1 country
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions Ended

2022-502701-15-00 1 country ELTROMBOPAG OLAMINE
Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions. Ended

2022-502702-32-00 1 country ELTROMBOPAG OLAMINE
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects Ended

2022-501327-25-00 1 country LENVATINIB; LENVATINIB MESILATE
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules in Healthy Subjects. Ended

2022-501325-20-00 1 country NILOTINIB; NILOTINIB HYDROCHLORIDE; NILOTINIB HYDROCHLORIDE MONOHYDRATE
Bioequivalence of Eltrombopag 25 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended

2023-504468-41-00 1 country
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions Ended

2024-512912-23-00 1 country

Showing 1–17 of 17 trials

← All sponsors A–Z